{
  "id": "cancer-cachexia",
  "title": "Cancer cachexia",
  "lang": "en",
  "source_lang": "en",
  "summary": "Cancer cachexia is a multifactorial syndrome of ongoing skeletal muscle loss, with or without fat loss, that cannot be fully reversed by conventional nutritional support.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "Cancer-associated cachexia",
    "cancer-related cachexia"
  ],
  "generated_at": "2026-11-05",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/cancer-cachexia/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/cancer-cachexia/",
      "json": "https://aiwiki.page/zh/cancer-cachexia.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Cancer cachexia is a multifactorial syndrome associated with cancer, characterized by ongoing loss of skeletal muscle, with or without loss of body fat, that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. It reflects a combination of reduced food intake and abnormal metabolism, including increased tissue breakdown. Unlike uncomplicated starvation, it involves disease-driven changes that make rebuilding muscle difficult even when additional nutrients are supplied."
    },
    {
      "heading": "Clinical features and significance",
      "text": "The main features are involuntary weight loss, muscle wasting, reduced strength, and declining physical function. Loss of appetite, early fullness after eating, and fatigue are common, but neither severe appetite loss nor an obviously underweight appearance is required. People with obesity can lose substantial muscle while retaining a relatively high body weight.\n\nCachexia is particularly common in advanced cancers and in cancers of the pancreas, stomach, and lung. Its frequency varies substantially with cancer type, disease stage, treatment, and the definition used. It is not restricted to the final weeks of life.\n\nCancer cachexia is associated with poorer health-related quality of life, reduced tolerance of anticancer treatment, more complications, and shorter survival. These relationships partly reflect the severity of the underlying cancer; cachexia is both a contributor to illness and a marker of disease burden. Weight loss alone does not establish how much an individual outcome is attributable to the syndrome."
    },
    {
      "heading": "Biological mechanisms",
      "text": "Cachexia develops through interactions among the tumour, the host response, and factors that reduce food intake. No single mechanism explains every case.\n\nReduced intake\n\nAppetite and food consumption may decline because of tumour-related signals, altered taste or smell, early satiety, difficulty swallowing, or gastrointestinal obstruction. Nausea, mouth problems, pain, and adverse effects of chemotherapy or other treatments can further limit intake.\n\nChanges in signalling to the hypothalamus, a brain region involved in appetite and energy regulation, can suppress hunger. These biological changes help explain why reduced eating is not simply a matter of preference or motivation.\n\nInflammation and altered tissue metabolism\n\nSystemic inflammation contributes to cachexia in many patients. Inflammatory signals can promote muscle protein breakdown, interfere with muscle protein synthesis, alter appetite, and affect fat metabolism. Insulin resistance and changes in hormonal signalling may further impair the use and storage of nutrients.\n\nMuscle loss results when protein breakdown persistently exceeds protein synthesis. Adipose tissue may also be depleted through increased fat breakdown. Resting energy expenditure is elevated in some patients, but not in all; reduced physical activity can simultaneously lower total daily energy expenditure. Cancer cachexia therefore cannot be explained simply as the tumour consuming calories.\n\nThe relative importance of these mechanisms differs between cancer types and between individuals. Findings from experimental models do not necessarily establish the dominant mechanism in a particular patient."
    },
    {
      "heading": "Definition and diagnostic criteria",
      "text": "A widely used international consensus definition, published in 2011, identifies cancer cachexia when any of the following is present:\n\n- Involuntary weight loss greater than 5% during the preceding six months, in the absence of simple starvation.\n- A body mass index below \\(20\\ \\mathrm{kg/m^2}\\), together with weight loss greater than 2%.\n- Low skeletal muscle mass consistent with sarcopenia, together with weight loss greater than 2%.\n\nThese criteria provide a common framework for clinical assessment and research, but they do not capture every aspect of the syndrome. Thresholds and methods for identifying low muscle mass vary across populations and studies.\n\nAssessment generally combines weight history, dietary intake, symptoms, physical function, and body composition. Computed tomography scans obtained during cancer care can provide measurements of skeletal muscle. Strength and physical performance tests offer information that body weight alone cannot supply.\n\nFluid retention, including edema, may conceal tissue loss. Laboratory measures such as inflammatory markers can support assessment, but no single biomarker establishes or excludes cancer cachexia. A low serum albumin concentration is not a specific measure of inadequate nutritional intake because inflammation and other disease processes also affect it."
    },
    {
      "heading": "Stages and related conditions",
      "text": "The consensus framework describes three broad stages:\n\n- Precachexia: early clinical and metabolic changes, including appetite loss and weight loss of no more than 5%.\n- Cachexia: established wasting meeting the diagnostic criteria.\n- Refractory cachexia: a stage associated with strongly catabolic disease that is no longer responsive to anticancer treatment, low functional status, and a short expected survival.\n\nNot everyone progresses through clearly separated stages, and the boundaries are not precise biological divisions. Refractory cachexia is not defined by weight loss alone.\n\nCancer cachexia overlaps with, but is not identical to, several other conditions:\n\n- Malnutrition is a broader category involving deficient or imbalanced nutrient intake or utilization. Cachexia commonly includes disease-related malnutrition, but nutritional deficiency alone does not explain it.\n- Sarcopenia is a muscle disorder characterized principally by low muscle strength, with low muscle quantity or quality used to confirm the diagnosis. Cancer cachexia often includes muscle depletion, but the terms are not interchangeable.\n- Starvation primarily reflects inadequate energy intake and is generally more responsive to feeding than cachexia.\n- Anorexia means loss of appetite in this context; it does not denote the psychiatric disorder anorexia nervosa.\n\nThe differential diagnosis of weight loss also includes treatment toxicity, malabsorption, endocrine disease, infection, and mechanical problems affecting eating. These conditions may coexist with cachexia."
    },
    {
      "heading": "Management and its limitations",
      "text": "Clinical management is usually multimodal because no single intervention addresses all components of the syndrome. Approaches described in oncology care include treatment of the underlying cancer, management of symptoms that impede eating, individualized nutritional support, and physical activity or rehabilitation adapted to functional capacity. These are components of clinical care rather than a universally effective reversal strategy.\n\nEffective anticancer treatment can reduce the processes driving cachexia in some patients. Nutritional interventions may improve intake and address nutrient deficits, but additional calories alone do not reliably reverse disease-driven muscle wasting. Tube feeding and intravenous nutrition have distinct indications, burdens, and risks; they are not established universal treatments for cachexia itself.\n\nSome medicines can improve appetite or body weight in selected circumstances. Short courses of corticosteroids and progestational agents have been studied for appetite-related outcomes. Their effects do not consistently translate into increased muscle strength or longer survival, and adverse effects limit their use. Drug availability and approved indications differ by jurisdiction.\n\nPalliative care addresses symptoms, function, emotional distress, and communication throughout serious illness, including alongside active cancer treatment. Eating and weight loss can become sources of distress or conflict within families. Explaining the biological nature of cachexia distinguishes disease-driven wasting from a failure to make sufficient effort to eat."
    },
    {
      "heading": "Research and measurement challenges",
      "text": "Cachexia studies use varied entry criteria and outcome measures, including appetite, body weight, lean body mass, strength, physical performance, and survival. These outcomes are not interchangeable: increased body weight may represent fat or fluid rather than restored muscle, and increased lean mass does not necessarily produce better function.\n\nRandomized controlled trials investigate nutritional, exercise-based, pharmacological, and combined approaches. Important methodological challenges include differences in cancer biology, concurrent treatments, disease stage, and the feasibility of participation during advanced illness. Demonstrating meaningful benefits in daily functioning and patient experience remains distinct from demonstrating a change in body composition."
    }
  ],
  "links": [
    "cancer",
    "metabolism",
    "fatigue",
    "obesity",
    "pancreatic-cancer",
    "stomach-cancer",
    "lung-cancer",
    "health-related-quality-of-life",
    "nausea",
    "pain",
    "chemotherapy",
    "hypothalamus",
    "inflammation",
    "insulin-resistance",
    "x-ray-computed-tomography",
    "edema",
    "biomarker",
    "malnutrition",
    "differential-diagnosis",
    "rehabilitation",
    "corticosteroid",
    "palliative-care",
    "randomized-controlled-trial"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}